Merck’s HIV prevention pill reaches poorest countries first

The drug is called alimatravir and is taken monthly as prevention against HIV infection. It is currently in late-stage clinical trials. Despite that, Merck has already concluded voluntary licensing agreements with seven generic manufacturers, three based in Africa and four in India. They are permitted to sell the pill in 129 low- and middle-income countries, royalty-free.

The timing is notable. Companies usually wait until a drug is approved before striking such deals. By acting now, generic manufacturers can scale up production and prepare for regulatory approvals in advance. The researchers and policymakers behind the deal aim to maximise access as soon as the drug receives approval.

Why this matters for longevity

HIV infection accelerates biological aging. People living with HIV age faster at the cellular level, an effect that partly persists even after successful treatment. A broadly accessible prevention tool therefore also touches on the longevity question: how do we prevent premature biological aging caused by avoidable infections?

What remains uncertain

Alimatravir has not yet been approved. Late-stage trials are still ongoing. It is not yet known whether the drug is as effective as existing prevention options such as PrEP, or whether its side-effect profile is comparable. The licensing deals expand potential reach, but efficacy still needs to be fully established.

The royalty-free structure is also commercially relevant: it makes it easier for generic producers to calculate costs and keep prices low. Whether that translates to broad availability in practice depends on distribution networks and local health systems.

Read the original article